In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...

KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...

The end of the Vertex-Verve collaboration comes as investors are reevaluating once sky-high expectations for the gene editing industry as commercial realities set in. Shares of Verve and top companies ...

A trend in gene therapy setbacks continues as Vertex Pharmaceuticals gave Verve Therapeutics back the rights to a liver disease gene editing program. The research and development deal dates back to ...

Data supplied by Morningstar and accurate on Sep 30, 2024. It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of ...